 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 GLOBE NEWSWIRE -- Hutchison China MediTech Limited HUTCHMED NasdaqAIM: HCM has initiated a Phase IbII study of surufatinib in combination with BeiGenes tislelizumab in patients with advanced solid tumors in the U.S. and Europe. The first patient was dosed on March 23, 2021. This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation of an immune response. 